6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples